reports
- Jacob Mekhael
MaaT Pharma Secures € 37.5m tranched EIB financing
MaaT announced that it has secured a € 37.5m , 4-tranche financing from the European Investment Bank (EIB), which bears interest at 7%. In addition, MaaT will issue warrants to the EIB with each tranche. MaaT's previously communicated cash runway was into January 2026, which should now extend beyond that point following this additional funding, though we do note that disbursement of Tranches B to D is subject to operational and financing conditions, which we'd be keen to learn more about. All in...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Thibault Leneeuw
- Wim Hoste
- Wim Lewi
Correction: Lacroix : First-half revenue of €291.5 million, down 12.3%...
Correction: Lacroix : First-half revenue of €291.5 million, down 12.3% on a like-for-like basis, reflecting challenging sector conditions for Electronics despite continued positive momentum in Environment PRESS RELEASE 23/07/2025 First-half revenue of €291.5 million, down 12.3% on a like-for-like basis, reflecting challenging sector conditions for Electronicsdespite continued positive momentum in Environment A better-oriented second half expected In the second quarter of 2025, LACROIX recorded consolidated revenue of €140.4 million, compared with €169.4 million for the...
Correction: Lacroix : Un chiffre d’affaires de 291,5 M€ au 1er semestr...
Correction: Lacroix : Un chiffre d’affaires de 291,5 M€ au 1er semestre, en repli de 12,3% à périmètre constant, reflétant le contexte sectoriel difficile pour Electronics malgré une dynamique positive sur Environment COMMUNIQUE DE PRESSE 23/07/2025 Un chiffre d’affaires de 291,5 M€ au 1er semestre, en repli de 12,3% à périmètre constant, reflétant le contexte sectoriel difficile pour Electronics malgré une dynamique positive sur Environment Un deuxième semestre mieux orienté Au deuxième trimestre 2025, LACROIX a enregistré un chiffre d’affaires consolidé de 140,4 mi...
Lacroix : First-half revenue of €291.5 million, down 12.3% on a like-f...
Lacroix : First-half revenue of €291.5 million, down 12.3% on a like-for-like basis, reflecting challenging sector conditions for Electronics despite continued positive momentum in Environment Revenue for the first half of 2025: €43.5 million, up +42.2% Paris, 23 July 2025 – Bilendi, a global leader in technology, data and AI solutions for the market research industry, announces its consolidated revenue for the first half of 2025, marked by a strong increase in sales of+ 42.2%. In € million, unaudited Q2 H1 2024 2025 Δ Δ at cer1 2024 2025 Δ ...
Lacroix : Un chiffre d’affaires de 291,5 M€ au 1er semestre, en repli ...
Lacroix : Un chiffre d’affaires de 291,5 M€ au 1er semestre, en repli de 12,3% à périmètre constant, reflétant le contexte sectoriel difficile pour Electronics malgré une dynamique positive sur Environment Chiffre d’affaires du 1er semestre 2025 : 43,5 M€, en hausse de +42,2% Paris, le 23 juillet 2025 – Bilendi, un leader mondial des technologies, des données et des solutions d'IA pour le secteur des études de marché, annonce son chiffre d’affaires consolidé du premier semestre 2025, marqué par une forte hausse de ses ventes de +42,2%. En M€, non audité T2 S1...
LACROIX : Bilan semestriel du contrat de liquidité
LACROIX : Bilan semestriel du contrat de liquidité COMMUNIQUE DE PRESSE 11/07/2025 BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ Au titre du contrat de liquidité confié par la société LACROIX Group à PORTZAMPARC – GROUPE BNP PARIBAS, à la date du 30 juin 2025, les moyens suivants figuraient au compte de liquidité : 7 763 titres LACROIX GroupEspèces : 40.142,70 euros Il est rappelé que lors du bilan semestriel du 31 décembre 2024, les moyens suivants figuraient au compte de liquidité : 7 994 titres LACROIX GroupEspèces : 37.231,89 euros Il est rappelé que lors de...
Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel ...
Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial. Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of June 30, 2025: ...
Genfit : Bilan semestriel du contrat de liquidité contracté avec le Cr...
Genfit : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 8 juillet 2025 – GENFIT (Nasdaq et Euronext: GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui le bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial. Au titre du contrat de liquidité confié par la société GENFIT au Crédit Industriel et Commercial, à la ...
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Jacob Mekhael
MaaT Pharma Partnership with Clinigen secures MaaT013's EU commerciali...
MaaT signed a licensing, distribution, and commercial supply agreement with Clinigen in Europe for Xervyteg (MaaT013, microbiome therapy, enema formulation) in aGvHD for a € 10.5m upfront, € 18m in milestones, and mid-thirties flat royalty on sales. We believe this deal serves as validation of MaaT013's potential, and see the partnership as a de-risking event for MaaT013's commercialisation in Europe, given Clinigen's experience commercialising in haemato-oncology, with 3 products currently on t...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Thomas Couvreur
- Jacob Mekhael
MaaT Pharma Business update highlights upcoming priorities, final ARES...
MaaT provides a business update, which reiterated the company's progress with respect to its pipeline, and following the previously announced EU regulatory submission for MaaT013 in aGvHD, the company continues to search for a commercialisation partner in Europe ahead of a potential approval in 2H26. Timeline for MaaT013 US trial launch shifts to 2026 (from 4Q25) to focus resources on the European opportunity. Looking ahead, data updates for MaaT013 in aGvHD (final results incl. 12-month OS), as...
GENFIT: June 17, 2025 Combined Shareholders Meeting Results
GENFIT: June 17, 2025 Combined Shareholders Meeting Results All resolutions recommended by the Board of Directors approved (quorum: 27.21%). Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 17, 2025. The quorum on first convening amounted to 27.21% and shareholders approved all of the resolutions, with...
GENFIT : Résultats de l’Assemblée Générale Mixte du 17 juin 2025
GENFIT : Résultats de l’Assemblée Générale Mixte du 17 juin 2025 L’ensemble des projets de résolutions recommandés par le Conseil d’Administration a été approuvé (quorum : 27,21%). Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 17 juin 2025 – GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui les résultats de son Assemblée Générale Mixte convoquée le 17 juin 2025. Le quorum réuni sur première convocation s’est é...
- Jacob Mekhael
MaaT Pharma Updated MaaT013 aGvHD EAP data at EHA shows consistent out...
MaaT reported updated early access program (EAP) results for MaaT013 (microbiome therapy, enema formulation) in aGvHD at EHA, being held 12-15 June. The data, which was previously shared in the abstract last month, shows that the response rates and overall survival observed in the steroid refractory and ruxulitinib resistant subset of patients (n=70) are in line with what was observed in the phase 3 ARES trial. In our view, this points to the consistency of outcomes with MaaT013 in this patient ...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Michiel Declercq
- Thomas Vranken
- Wim Lewi
- Jacob Mekhael
MaaT Pharma Completes EU regulatory submission for MaaT013 in aGvHD
MaaT announced the submission of the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its lead drug candidate MaaT013 (microbiome therapy, enema formulation) in aGvHD under the brand name Xervyteg. Potential approval could be granted in 2H26, and MaaT is actively exploring strategic partnerships to commercialise MaaT013 in Europe. We believe the solid phase 3 results and good uptake in the early access program will be supportive of MaaT013's commercial launch ...
- Guy Sips
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Maria Vara
- Oscar Haffen Lamm
- Valliant Campagne
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.